Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd ADR (TEVA)

Teva Pharmaceutical Industries Ltd ADR (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,480,209
  • Shares Outstanding, K 1,092,190
  • Annual Sales, $ 16,659 M
  • Annual Income, $ -3,990 M
  • 60-Month Beta 1.44
  • Price/Sales 0.57
  • Price/Cash Flow 2.43
  • Price/Book 0.92
Trade TEVA with:

Options Overview Details

View History
  • Implied Volatility 36.53%
  • Historical Volatility 19.48%
  • IV Percentile 15%
  • IV Rank 6.62%
  • IV High 117.94% on 03/05/21
  • IV Low 30.76% on 08/05/21
  • Put/Call Vol Ratio 0.32
  • Today's Volume 30,620
  • Volume Avg (30-Day) 26,876
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 803,481
  • Open Int (30-Day) 970,745

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.63
  • Number of Estimates 3
  • High Estimate 0.64
  • Low Estimate 0.62
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.59 +1.63%
on 09/21/21
9.65 -9.53%
on 09/08/21
-0.41 (-4.49%)
since 08/20/21
3-Month
8.24 +5.95%
on 07/19/21
10.49 -16.75%
on 06/25/21
-1.42 (-13.99%)
since 06/22/21
52-Week
8.24 +5.95%
on 07/19/21
13.30 -34.36%
on 02/09/21
-0.12 (-1.36%)
since 09/22/20

Most Recent Stories

More News
Biosimilar Market Report 2021: Increased Investments, Product Launches, and Collaborations to Spur Growth – Forecast to 2026

The is expected to exceed more than US$ 23.50 Billion by 2024 at a CAGR of 31% in the given forecast period.

PFE : 43.95 (+0.07%)
TEVA : 8.73 (+0.58%)
AMGN : 213.64 (-0.80%)
Global Myeloproliferative Disorder (MPD) Treatment Market – Research on Industry Size, Business Global Status by Top Key Players, Share Analysis with Demand Growth, Gross Margin Analysis Forecast till 2021-2029

Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and...

BMY : 60.15 (-0.30%)
INCY : 69.59 (-8.51%)
NOVN : 8.40 (-0.36%)
PFE : 43.95 (+0.07%)
TEVA : 8.73 (+0.58%)
Methotrexate Drug Market- Key Business Opportunities, Impressive Growth Rate and Development Analysis to 2028

Research Nester published a report titled  which delivers a detailed overview of the Methotrexate  Drug market in terms of market segmentation by type, by route of administration, by application, by...

AMRX : 5.04 (+0.20%)
TEVA : 8.73 (+0.58%)
PFE : 43.95 (+0.07%)
ENDP : 3.01 (+9.06%)
Global Myeloproliferative Disorder (MPD) Treatment Market to Grow Owing to Rising Prevalence of Myeloproliferative Disorders Among Individuals till 2029

Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and...

BMY : 60.15 (-0.30%)
INCY : 69.59 (-8.51%)
NOVN : 8.40 (-0.36%)
PFE : 43.95 (+0.07%)
TEVA : 8.73 (+0.58%)
Growth Hormone Deficiency Market: Company Profiles, Growth Strategy, Developing Technologies, Opportunities and Forecast by Regions till 2028

Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution...

TEVA : 8.73 (+0.58%)
NOVN : 8.40 (-0.36%)
PFE : 43.95 (+0.07%)
LLY : 228.30 (-0.81%)
MRK : 72.04 (+0.10%)
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028

Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation...

CLRB : 0.9819 (+2.26%)
PFE : 43.95 (+0.07%)
LLY : 228.30 (-0.81%)
AZN.LN : 8,684.000 (+0.78%)
TEVA : 8.73 (+0.58%)
BMY : 60.15 (-0.30%)
MGNX : 21.51 (-0.69%)
JNJ : 163.93 (-0.36%)
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll

Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered...

INNO.CN : 1.110 (-10.48%)
INNPF : 0.8639 (+20.91%)
TEVA : 8.73 (+0.58%)
PSTI : 2.93 (-1.01%)
BCLI : 3.41 (-0.58%)
Wilson Disease Drugs Market: Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2029

Research Nester has released a report titled "" which delivers detailed overview of the global Wilson disease drugs market in terms of market segmentation by indication, drug type, end-user and by region....

MRK : 72.04 (+0.10%)
BHC : 28.39 (+0.64%)
ALXN : 182.50 (+1.70%)
KDMN : 8.86 (+0.68%)
TEVA : 8.73 (+0.58%)
InnoCan Pharma receives strong buy recommendation: Here is why

Those who invested in InnoCan Pharma's (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) a year ago are up 273%.

INNO.CN : 1.110 (-10.48%)
INNPF : 0.8639 (+20.91%)
TEVA : 8.73 (+0.58%)
PSTI : 2.93 (-1.01%)
BCLI : 3.41 (-0.58%)
Injectable Drugs for Type-2 Diabetes Market Evaluation, Competition Tracking, And Regional Analysis 2028

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028" which delivers detailed overview of the global injectable drugs for type-2 diabetes market in terms of market...

GSK.LN : 1,428.000 (-0.07%)
MRK : 72.04 (+0.10%)
TEVA : 8.73 (+0.58%)
MYL : 15.86 (+1.96%)
AZN.LN : 8,684.000 (+0.78%)
LLY : 228.30 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

3rd Resistance Point 9.03
2nd Resistance Point 8.96
1st Resistance Point 8.85
Last Price 8.73
1st Support Level 8.67
2nd Support Level 8.60
3rd Support Level 8.49

See More

52-Week High 13.30
Fibonacci 61.8% 11.37
Fibonacci 50% 10.77
Fibonacci 38.2% 10.17
Last Price 8.73
52-Week Low 8.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar